

PHARMACY POLICY STATEMENT

Common Ground Healthcare Cooperative (CGHC)

DRUG NAME	Joenja (leniolisib)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Joenja, approved by the FDA in 2023, is a small molecule kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3K δ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. It selectively targets PI3K δ signaling by inhibiting its hyperactive subunit.

APDS is also known as p110 δ -activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI). It is an ultra-rare disease of primary immunodeficiency caused by variants in either of the genes encoding the PI3K δ heterodimer (*PIK3CD* in APDS1 or *PIK3R1* in APDS2) which leads to hyperactive PI3K δ signaling. This results in disrupted immune cell development and function. Clinical manifestations include infections, nonmalignant lymphoproliferation, autoimmunity (e.g., cytopenias), enteropathy, bronchiectasis, and increased risk of lymphoma.

In a Phase 3 study, Joenja met the coprimary endpoints of reducing lymphadenopathy and normalizing immune cell subsets. It is the first FDA-approved drug for APDS.

Joenja (leniolisib) will be considered for coverage when the following criteria are met:

Activated Phosphoinositide 3-Kinase Delta (PI3K δ) syndrome (APDS)

For **initial** authorization:

1. Member is at least 12 years of age; AND
2. Medication must be prescribed by or in consultation with an immunologist or hematologist; AND
3. Member has a diagnosis of APDS confirmed by an APDS-associated genetic PI3K δ mutation with a documented variant in either *PIK3CD* or *PIK3R1*; AND
4. Chart notes must show clinical findings/manifestations of APDS (e.g., history of repeated oto-sino-pulmonary infections, at least 1 measurable nodal lesion by CT or MRI).
5. **Dosage allowed/Quantity limit:** Weight 45 kg or greater: 70 mg orally twice daily.
(QL: 60 tablets per 30 days)

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes must show positive clinical response such as reduced lymph node size, increased naïve B cell percentage (out of total B cells), reduced spleen volume, or improved cytopenias.

If all the above requirements are met, the medication will be approved for an additional 12 months.



HEALTHCARE COOPERATIVE

CareSource considers Joenja (leniolisib) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
04/24/2023	New policy for Joenja created.
03/07/2024	Added reference. Moved measurable nodal lesion to list of clinical findings rather than an additional requirement. Removed restriction for concurrent use with an immunosuppressive medication.

References:

1. Joenja [prescribing information]. Pharming Technologies B.V.; 2023.
2. Rao VK, Webster S, Šedivá A, et al. A randomized, placebo-controlled phase 3 trial of the PI3K δ inhibitor leniolisib for activated PI3K δ syndrome. *Blood*. 2023;141(9):971-983. doi:10.1182/blood.2022018546
3. Rao VK, Webster S, Dalm VASH, et al. Effective "activated PI3K δ syndrome"-targeted therapy with the PI3K δ inhibitor leniolisib. *Blood*. 2017;130(21):2307-2316. doi:10.1182/blood-2017-08-801191
4. Coulter TI, Cant AJ. The Treatment of Activated PI3K δ Syndrome. *Front Immunol*. 2018;9:2043. Published 2018 Sep 7. doi:10.3389/fimmu.2018.02043
5. Singh A, Joshi V, Jindal AK, Mathew B, Rawat A. An updated review on activated PI3 kinase delta syndrome (APDS). *Genes Dis*. 2019;7(1):67-74. Published 2019 Oct 14. doi:10.1016/j.gendis.2019.09.015
6. Rao VK, Kulm E, Šedivá A, et al. Interim analysis: Open-label extension study of leniolisib for patients with APDS. *J Allergy Clin Immunol*. 2024;153(1):265-274.e9. doi:10.1016/j.jaci.2023.09.032

Effective date: 01/01/2025

Revised date: 03/07/2024